Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Yake Biotechnology Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Clinical Study on the Safety and Effectiveness of CLL1 CAR-T Cells in the Treatment of CLL1-positive Hematological Malignancies
Human C-type lectin-like molecule 1 (CLL1) is a type II transmembrane glycoprotein ，CLL1 expression is restricted to bone marrow cells and most AML blasts. In addition, CLL1 is expressed in leukemia stem cells (LSC) but not in hematopoietic stem cells (HSC), may provide a potential therapeutic target for the treatment of AML.The CAR-T cell injection uses immune cells from healthy donors, and is the final product obtained after CAR genetic modification, cell expansion, culture, screening, preparation, sub-packaging, and release inspection. The center intends to apply for a clinical trial of CLL1 CAR-T cells to treat CLL1-positive hematological malignancies on the basis of preliminary research.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment of CLL1-positive Hematological Malignancies | Experimental | Administration of CLL1 CAR T-cells A dose levels of 2-8*10E6/kg are administrated for each subject. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CLL1 CAR T-cells | Biological | Drug: CLL1 CAR T-cells Each subject receive CLL1 CAR T-cells by intravenous infusion Other Name: CLL1 CAR T-cells injection |
|
| Measure | Description | Time Frame |
|---|---|---|
| Dose-limiting toxicity (DLT) | Adverse events assessed according to NCI-CTCAE v5.0 criteria | Baseline up to 28 days after CLL1 CAR T-cells infusion |
| Incidence of treatment-emergent adverse events (TEAEs) | Incidence of treatment-emergent adverse events [Safety and Tolerability] | Up to 90 days after CLL1 CAR T-cells infusion |
| Measure | Description | Time Frame |
|---|---|---|
| Concentration of CAR-T cells | In peripheral blood and bone marrow | From admission to the end of the follow-up, up to 2 years |
| Disease control rate, DCR | The percentage of patients with remission and stable disease after treatment in the total evaluable cases. |
Not provided
Inclusion Criteria:
1. Patients is histologically diagnosed with CLL1-positive AML according to the NCCN Clinical Practice Guidelines in Oncology：Acute Myeloid Leukemia（Version 2.2021） 2. The diagnosis is consistent with r/r CLL1 + AML, and includes any of the following conditions:
No CR was obtained after 2 courses of standard chemotherapy
The first induction was CR, but the duration of CR was less than 12 months
No CR was obtained after the first or multiple remedial treatment;
Relapse twice or more; 3. The number of blast cells in bone marrow was more than 5% (morphology) and / or > 1% (flow cytometry).
4. No active lung infection, inhaled air oxygen saturation ≥92% 5. The estimated survival time is more than 3 months 6. ECOG score was 0-2 7. The patients or their legal guardians voluntarily participated in the trial and signed the informed consent.
Exclusion Criteria:
1. Patients with history of epilepsy or other central nervous system diseases; 2. Patients with prolonged QT or severe heart disease; 3. Pregnant or lactating women (the safety of this therapy for unborn children is unknown); 4. The patients with uncontrolled active infection; 5. Active hepatitis B or hepatitis C virus infection; 6. Previous application of gene therapy; 7. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal; 8. Serum creatinine > 2.5mg/dl or ALT / AST > 3 times ULN or bilirubin > 2.0mg/dl; 9. Those who suffer from other uncontrolled diseases are not suitable to join the study; 10. HIV infection; 11. Any situation that the researchers believe may increase the risk of patients or interfere with the test results.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| He Huang, PhD | Contact | +8613605714822 | hehuangyu@126.com | |
| Yongxian Hu, PhD | Contact | +8615957162012 | huyongxian2000@aliyun.com |
| Name | Affiliation | Role |
|---|---|---|
| He Huang, PhD | First Affiliated Hospital of Zhejiang University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The first affiliated hospital of medical college of zhejiang university | Recruiting | Hangzhou | Zhejiang | 310003 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| From Day 28 CLL1 CAR-T infusion up to 2 years |
| Duration of remission, DOR | The time from the first assessment of remission or partial remission of the disease to the first assessment of disease progression or death from any cause | 24 months post CLL1 CAR-T cells infusion |
| Progression-free survival, PFS | The time from cell reinfusion to the first assessment of disease progression or death from any cause | 24 months post CLL1 CAR-Tcells infusion |
| Overall survival, OS | The time from the cell reinfusion to death due to any cause | From CLL1 CAR-T infusion to death,up to 2 years |
| The First Hospital of Zhejiang Medical Colleage Zhejiang University | Recruiting | Hangzhou | Zhejiang | 310003 | China |
|